🇺🇸 FDA
Pipeline program

Placebo with a matching appearance to 100 mg niraparib capsules, filled with an excipient blend for clinical development., NIRAPARIB TOSILATE MONOHYDRATE

PR-30-5017-C

Phase 3 small_molecule active

Quick answer

Placebo with a matching appearance to 100 mg niraparib capsules, filled with an excipient blend for clinical development., NIRAPARIB TOSILATE MONOHYDRATE for Homologous recombination deficiency advanced ovarian cancer is a Phase 3 program (small_molecule) at TESARO Bio Netherlands B.V. with 1 ClinicalTrials.gov record(s).

Program details

Company
TESARO Bio Netherlands B.V.
Indication
Homologous recombination deficiency advanced ovarian cancer
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials